Premium
The importance of miRNAs and epigenetics in acute lymphoblastic leukemia prognosis
Author(s) -
Ranjbar Reza,
Karimian Ansar,
Aghaie Fard Arad,
Tourani Mehdi,
Majidinia Maryam,
JadidiNiaragh Farhad,
Yousefi Bahman
Publication year - 2019
Publication title -
journal of cellular physiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.529
H-Index - 174
eISSN - 1097-4652
pISSN - 0021-9541
DOI - 10.1002/jcp.26510
Subject(s) - epigenetics , microrna , dna methylation , biology , progenitor cell , leukemia , effector , non coding rna , cancer research , lymphoblastic leukemia , methylation , epigenesis , epigenetic therapy , gene , bioinformatics , stem cell , immunology , gene expression , genetics
Acute lymphoblastic leukemia (ALL), one of the most common malignant human disorders, originates in different important genetic lesions in T‐cell or B‐cell progenitors. ALL is a malignant lymphoid progenitor with peak prevalence in children (2–5 years). The rate of survival when one is suffering from ALL depends on various agents including the age of the patient, responses to anti‐leukemic therapy, and cell biology. miRNAs and epigenetics are important regulatory factors in the expression of genes. miRNAs are noncoding RNA with inhibitory effectors on specific mRNA. Patterns of DNA methylation are profoundly changed in ALL by epigenetic mechanisms. The deciphering of miRNA and the epigenetic pathogenesis in ALL could revolutionize response to the therapy and outcome, and create an enormous promise for novel approaches to reduce the toxic side‐effects of intensive leukemia. Hence, pathogenetic miRNAs and epigenetics leading to the initiation and the progression of ALL are summarized in this review.